2. Academic Validation
  3. A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants

A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants

  • Bioorg Med Chem. 2022 Jun 15;64:116760. doi: 10.1016/j.bmc.2022.116760.
Shangjiu Hu 1,  Ling Ma 1,  Biao Dong 1,  Qi Shan 2,  Jinming Zhou 3,  Guoning Zhang 1,  Minghua Wang 1,  Shan Cen 1,  Mei Zhu 4,  Juxian Wang 5,  Yucheng Wang 6
Affiliations

Affiliations

  • 1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
  • 2 Tianjin Institute of Pharmaceutical Research, Tianjin 300462, China.
  • 3 Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua 321004, China.
  • 4 Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China. Electronic address: [email protected].
  • 5 Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China. Electronic address: [email protected].
  • 6 Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China. Electronic address: [email protected].
PMID: 35483138 DOI: 10.1016/j.bmc.2022.116760
Abstract

Based upon the preliminary design of enhancing genetic barrier to drug-resistant viral mutants by maximizing hydrogen-bonding or other van der Waals contacts, we have designed, synthesized and biologically evaluated a new class of HIV-1 Protease Inhibitors with phenol derived P2 ligands and nitro or halogens in P2' ligands. Results indicate that a majority of inhibitors exhibit robust Enzyme inhibitory with IC50 values in picomolar or single digit nanomolar ranges. Among which, compound 17d displays potency with IC50 value of 21 pM and high protease selectivity. Of note, 17d exhibits greater Antiviral activity against the DRV-resistant variant than the efficacy against the wild type virus. Furthermore, the molecular modeling studies demonstrate important interactions between 17d and the active sites of both the wild-type and DRV-resistant HIV-1 protease, as well as furnish insights for further optimization of new inhibitors.

Keywords

Antiviral activity; DRV-resistant; HIV-1 protease; Molecular docking; Phenols.

Figures
Products